DNA SEQ 2, INC. filed a Form D with the Securities and Exchange Commission on 2026-03-11.
DNA SEQ 2, INC. filed a Form D notice of an exempt securities offering with the SEC on March 11, 2026. The filing reports $1.18M sold. Its industry group is Pharmaceuticals. It names Andrew Nappin (Executive Officer), Stuart Siegel (Director), Janusz Sowadski (Director) (SEC Form D, March 11, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like DNA SEQ 2, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-03-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns DNA SEQ 2, INC.
Free to see. No signup.
More on the people and the money behind DNA SEQ 2, INC., from the filings we hold.
Pharmaceuticals raises by companies based in California, filed within 90 days of this one, largest first.
Get an email when DNA SEQ 2, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when DNA SEQ 2, INC. raises, hires or launches. No email unless you switch it on.
Watch DNA SEQ 2, INC. →Get the full cited report on DNA SEQ 2, INC.
What the filing shows about DNA SEQ 2, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on DNA SEQ 2, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives DNA SEQ 2, INC.'s address as 1255 E Vista Way #157, Vista, CA 92084.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
DNA SEQ 2, INC. is a registered filer with the SEC (CIK 2115201) and has filed since 2026-03-11. 1 filing is on record, the latest on 2026-03-11.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
DNA SEQ 2, INC.'s Form D of 2026-03-11 names Andrew Nappin, Stuart Siegel, Janusz Sowadski and 3 more as its officers, directors or promoters.
Its new offerings report $1.18M sold across 1 offering, as its own filings state.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $1.18M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Andrew Nappin is named as Executive Officer on the Form D that DNA SEQ 2, INC. filed with the SEC on 11 March 2026, one of 6 people that filing names.
Stuart Siegel is named as Director on the Form D that DNA SEQ 2, INC. filed with the SEC on 11 March 2026, one of 6 people that filing names.
Janusz Sowadski is named as Director on the Form D that DNA SEQ 2, INC. filed with the SEC on 11 March 2026, one of 6 people that filing names.
Eric Ladizinsky is named as Director on the Form D that DNA SEQ 2, INC. filed with the SEC on 11 March 2026, one of 6 people that filing names.
Thomas Wheeler is named as Director on the Form D that DNA SEQ 2, INC. filed with the SEC on 11 March 2026, one of 6 people that filing names.
Benjamin Anderson is named as Director on the Form D that DNA SEQ 2, INC. filed with the SEC on 11 March 2026, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2026-03-11 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about DNA SEQ 2, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on DNA SEQ 2, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DNA SEQ 2, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist DNA SEQ 2, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind DNA SEQ 2, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for DNA SEQ 2, INC.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/dna-seq-2-inc-form-d-26000001